Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Google Secures Pentagon AI Deal for Classified Projects 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
SAN DIEGO, Feb. 03, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET in New York City.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner, Stern Investor Relations, Inc. 212.362.1200, [email protected]
